China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
NEW YORK - agilon health, inc. (NYSE:AGL) announced it received a notice from the New York Stock Exchange on November 5 informing the company that it no longer complies with continued listing standards as its average closing stock price fell below $1.00 over a consecutive 30 trading-day period ending November 4. The healthcare company's stock is currently trading at $0.70, down 75% over the past year, with a market capitalization of approximately $289 million.
The healthcare company, which partners with physician groups to transition to value-based care models, plans to notify the NYSE by November 19 of its intention to remain listed. To regain compliance, agilon intends to pursue a reverse stock split, subject to stockholder approval at its annual general meeting in 2026. InvestingPro data shows the stock is trading at just 1.02% above its 52-week low of $0.69, having declined nearly 80% over the past six months.
The notice does not immediately impact the listing of agilon's common stock, which will continue to trade on the NYSE during a cure period, provided the company maintains compliance with other NYSE listing standards. The company stated that the notice is not expected to affect its ongoing business operations or SEC reporting requirements. Despite financial challenges, including a negative EBITDA of $341 million in the last twelve months, agilon maintains a current ratio of 1.08 and holds more cash than debt on its balance sheet.
agilon health operates in 30 communities across the United States, working with approximately 2,200 primary care physicians through its platform that supports the transition to value-based care models for senior patients. The company reported revenue of $5.89 billion in the last twelve months, with a revenue growth of 5.21%, but suffers from weak gross profit margins of -1.83%.
The company has faced challenges recently, with a history of net losses mentioned in its forward-looking statements. agilon noted various risk factors in its announcement, including potential difficulties in executing growth initiatives and maintaining contracts with Medicare Advantage payors.
This article is based on information from a company press release.
In other recent news, Agilon Health reported a larger-than-expected loss in its Q3 2025 earnings. The company posted earnings per share (EPS) of -$0.27, missing the forecasted -$0.15, which represents an 80% surprise. Despite this, Agilon Health's revenue slightly exceeded expectations, reaching $1.44 billion compared to the projected $1.42 billion. The earnings report highlighted ongoing challenges in the Medicare Advantage market. The company's financial performance has drawn attention from investors and analysts alike. While the earnings results were below expectations, the revenue beat indicates some positive momentum. No updates were provided on any potential mergers or acquisitions. Analyst firms have yet to release any upgrades or downgrades following these recent developments. Investors are closely monitoring how Agilon Health navigates these challenges moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.